Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study
- 28 April 2008
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 23 (8), 1130-1136
- https://doi.org/10.1002/mds.22063
Abstract
Continuous subcutaneous apomorphine infusion (CSAI) is, at present, an alternative option for advanced Parkinson's disease (PD) with motor fluctuations. We studied the evolution of patients with PD and severe motor fluctuations long‐term treated with CSAI. We reviewed data from 82 patients with PD (mean age, 67 ± 11.07; disease duration, 14.39 ± 5.7 years) and severe motor fluctuations referred to 35 tertiary hospitals in Spain. These patients were long‐term treated (for at least 3 months) with CSAI and tolerated the procedure without serious side effects. We compared the baseline data of these 82 patients (before CSAI) with those obtained from the last follow‐up visit of each patient. The mean follow‐up of CSAI was 19.93 ± 16.3 months. Mean daily dose of CSAI was 72.00 ± 21.38 mg run over 14.05 ± 1.81 hours. We found a statistically significant reduction in off‐hours, according to self‐scoring diaries (6.64 ± 3.09 vs. 1.36 ± 1.42 hours/day, P < 0.0001), total and motor UPDRS scores (P < 0.0001), dyskinesia severity (P < 0.0006), and equivalent dose of antiparkinsonian therapy (1,405 ± 536.7 vs. 800.1 ± 472.9 mg of levodopa equivalent units P < 0.0001). CSAI is an effective option for patients with PD and severe fluctuations, poorly controlled by conventional oral drug treatment. © 2008 Movement Disorder Society.Keywords
This publication has 30 references indexed in Scilit:
- CONTINUOUS APOMORPHINE INFUSION (CAI) AND NEUROPSYCHIATRIC DISORDERS IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE: A FOLLOW-UP OF TWO YEARSArchives of Gerontology and Geriatrics, 2004
- Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patientsMovement Disorders, 2002
- Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Apomorphine infusional therapy in parkinson's disease: Clinical utility and lack of toleranceMovement Disorders, 1995
- Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five yearsMovement Disorders, 1993
- Comparison of motor response to apomorphine and levodopa in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- Subcutaneous apomorphine in the treatment of Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- SUBCUTANEOUS APOMORPHINE FOR ON-OFF OSCILLATIONS IN PARKINSON'S DISEASEThe Lancet, 1988
- SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONSThe Lancet, 1988
- Similarities between Neurologic Effects of L-Dopa and of ApomorphineNew England Journal of Medicine, 1970